Carnitine palmitoyltransferase
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
* '''CPT II''' exchanges the carnitine by CoA, enabling the oxidation of the long-chain fatty acids.<ref>PMID:15363638</ref> | * '''CPT II''' exchanges the carnitine by CoA, enabling the oxidation of the long-chain fatty acids.<ref>PMID:15363638</ref> | ||
| - | See also [[Beta | + | See also [[Beta oxidation]]. |
==Disease == | ==Disease == | ||
Current revision
| |||||||||||
3D structures of carnitine palmitoyltransferase
Updated on 16-January-2024
2le3 – hCPT I regulatory domain – human - NMR
2m76 - hCPT I regulatory domain – NMR
2h4t, 2fyo, 2deb – rCPT II – rat
2fw3 - rCPT II + antidiabetic drug
2rcu – rCPT II + substrate analog
4ep9, 4eph, 4eyw - rCPT II + inhibitor
References
- ↑ Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004 Oct-Dec;25(5-6):495-520. PMID:15363638 doi:http://dx.doi.org/10.1016/j.mam.2004.06.004
- ↑ Rufer AC, Lomize A, Benz J, Chomienne O, Thoma R, Hennig M. Carnitine palmitoyltransferase 2: analysis of membrane association and complex structure with a substrate analog. FEBS Lett. 2007 Jul 10;581(17):3247-52. Epub 2007 Jun 8. PMID:17585909 doi:10.1016/j.febslet.2007.05.080
